Peptide Therapy

Peptide Therapy

There are many potential benefits of peptide therapy in different medical fields. This Cureus article explores the expression of antimicrobial peptides and cytokines in the human omentum following abdominal surgery, with the aim of understanding how these peptides can aid in the prevention of postoperative infections. The article below focuses on the effects of Mechano-Growth Factor (MGF) peptide, which has been shown to have favorable impacts on muscle growth, wound healing, cartilage repair, and brain development in animal studies. MGF peptide has also been shown to activate muscle stem cells and enhance heart health, among other benefits. 

There is a growing interest in peptide therapy as a potential solution to various medical problems, from muscle loss to postoperative infections.

Sponsored Content

Cardiological Effects of MGF Peptide

Mechano-Growth Factor (MGF) peptide is a splice variant of insulin-like growth factor [i] that has been demonstrated to have cardiological effects, favorably influencing muscle growth, wound healing, cartilage repair, and brain development in animal studies. MGF C-terminal has been shown to enhance muscle healing after damage and hasten recovery time. Moreover, some evidence is that it helps shield tissues from the mechanical stressors incurred during weight training and jogging, according to research.

Do you have a Ph.D. or MD and need to purchase MGF peptides for your research? You can find high-quality, affordable peptides online.

What is the Mechano Growth Factor?

In contrast to IGF1, the peptide known as Mechano growth factor (MGF) [ii] have a slightly modified sequence. According to studies, it significantly impacts youngsters’ growth and development. There’s more, however.

Animal studies support that MGF peptide may promote tissue repair and development by activating muscle stem cells and increasing protein synthesis for tissue growth. Researchers are now exploring this peptide as a potential therapy for disorders that cause muscle loss and wasting in animals.

Mechanism of Action of the MGF Peptide

According to research, IGF and muscle growth factor (MGF) work together to cause hypertrophy and speed up the healing process after muscle injury. Overtraining the muscle and increasing tissue healing are two ways that MGF shows itself. Muscle satellite cells, also known as stem cells, are activated with their help, per clinical trial results. [v]

The IGF-1Eb isoform, as it’s more often known, protects neurons, mitigates the atrophying effects of insulin, and speeds up the healing of damaged muscle tissue in animals.

Studies in rats have shown the efficacy of this peptide. After muscular damage, high levels of MGF were found in the rats’ muscles, which promoted skeletal muscle cell development. Research on MGF treatment for disorders that cause muscle wasting or tissue damage is limited, but early results are encouraging.

Advantages of MGF Peptides

According to the scientific community’s findings, MGF peptides have a wide range of applications. In a nutshell, here’s what it can do, according to animal studies:

  • Encourage the growth of new muscle by stimulating stem cells
  • Facilitate healing, repair, and cell division
  • Facilitate the reduction of inflammation
  • Maximize workouts
  • Improve mental well-being and growth
  • Enhance heart health

Muscle Growth Factor’s Effects

Recent studies have shown that MGF (Mechanical growth factor) may stimulate satellite cells in the body, leading to increased hypertrophy, larger muscles, and even muscle regeneration. According to animal studies, MGF administered to mice for three weeks resulted in a 25% increase in muscle growth. Researchers think this peptide has the potential to double the health benefits of exercise and cure muscle-wasting disorders.

An animal’s basal metabolic rate and the pace at which it burns calories at rest benefit from muscle gain. Thus the animal may see more than simply an aesthetic advantage from exercising. Animal studies have demonstrated that increased lean body mass helps alleviate various diseases and health problems linked to obesity.

Transplantation of myogenic precursor cells enhances dystrophin expression, which may explain why MGF therapy is effective in the context of some muscle-wasting illnesses like Duchenne muscular dystrophy (DMD). As a result, the negative consequences of these states are mitigated.

Despite the treatment’s encouraging name, post-transplant survival statistics are dismal. Animal studies suggest that C-terminal peptide may improve transplant outcomes by increasing the number of myogenic precursor cells that survive the procedure.

Results of MGF on Injury Repair

Injuries, inflammatory diseases like arthritis, and overuse of joints may all lead to cartilage breakdown. Experts agree that poor blood flow and a lack of stem cells prevent cartilage from regenerating properly. Yet, research on MGF peptides in animals showed that they might assist in overcoming many of the obstacles to cartilage regeneration.

Research indicates that C-terminal [iii] MGF helps chondrocytes (cells that promote cartilage health and repair) endure exposure to noxious stimuli, including damage and physical stress. By increasing cell survival, MGF supplementation aids in protecting and repairing cartilage when mechanical stress is applied, as per studies.

Rodent studies showed that MGF peptide might stop disc degeneration by stopping cell apoptosis. [iv] 

Cardiological Consequences

Evidence from animal trials of acute myocardial infarction in sheep suggests that MGF peptide therapy may prevent heart muscle damage caused by ischemia. Researchers also found that cardiomyocyte damage was reduced by 35% when MGF peptide was administered.

Effects on Neuronal Health

In 2010, scientists proved that MGF peptide was present in the brains of rats, proving the medication’s potent neuroprotective properties. Research in mice further indicates that MGF protein is expressed in the context of brain hypoxia and that it may protect neurons.


Studies show that treatment with MGF peptide relieves the increasing muscular weakness seen in Lou Gehrig’s disease (ALS) and slows down the underlying cause of the illness, the degeneration of motor neurons.

Researchers have observed that Mechano-growth factor peptide protects neurons from disease progression more effectively than any other isoform. It may also aid in the recovery of brain tissue damaged by ischemia. Scientists have high hopes that MGF peptide, with further study, may prove to be therapeutic that can save motor neurons from dying.

References

[i] Philippou A, Papageorgiou E, Bogdanis G, Halapas A, Sourla A, Maridaki M, Pissimissis N, Koutsilieris M. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo. 2009 Jul-Aug;23(4):567-75. https://pubmed.ncbi.nlm.nih.gov/19567392/

[ii] Moriggl, R, V Gouilleux-Gruart, R Jähne, S Berchtold, C Gartmicen, X Liu, L Hennighausen, A Sotiropoulos, B Groner, and F Gouilleux. “Deletion of the Carboxyl-Terminal Transactivation Domain of MGF-Stat5 Results in Sustained DNA Binding and a Dominant Negative Phenotype.” Molecular and Cellular Biology 16, no. 10 (October 1996): 5691–5700. doi:10.1128/mcb.16.10.5691.

[iii] Esposito, Simone, Koen Deventer, and Peter Van Eenoo. “Characterization and Identification of a C-Terminal Amidated Mechano Growth Factor (MGF) Analogue in Black Market Products.” Rapid Communications in Mass Spectrometry 26, no. 6 (February 10, 2012): 686–692. doi:10.1002/rcm.6144.

[iv] Liu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019 May 17;10:601. https://pubmed.ncbi.nlm.nih.gov/31164836/

[v] Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007 Oct;7(10):2247-59. https://pubmed.ncbi.nlm.nih.gov/17845560/

Editor’s Note: This blog post was sponsored by Core Peptides LLC.

Cohesive Mitigation School Strategies as Protective Factors Against the Increase of COVID-19 Cases

Cohesive Mitigation School Strategies as Protective Factors Against the Increase of COVID-19 Cases

The Marin Independent Journal picked up an article published in Cureus about cohesive mitigation school strategies as protective factors against the increase of COVID-19 cases. 

By KERI BRENNER | kbrenner@marinij.com | Marin Independent Journal

PUBLISHED: December 6, 2021 at 4:17 p.m.

COVID-19 infections declined in Marin as schools in the county reopened for in-person learning last year, according to a new study.

The study, published last month in the peer-reviewed national medical journal Cureus, tracked attendance at 77 transitional kindergarten through eighth-grade Marin schools from Sept. 8, 2020, to Jan. 21.

Researchers found a correlation between having more students in class in person and lower COVID-19 rates in the community. That was in contrast to school breaks — such as Halloween and holiday time off in December — when cases spiked, said study co-author Dr. Michaela George, an epidemiologist and assistant professor at Dominican University of California in San Rafael.

“It shows that when schools follow the advice of their local public health officials and there is a good collaboration with local educators, kids can stay safe in the classroom,” George said…

Read the full article from the Marin Independent Journal here. 
Read the Cureus article here.

Cureus Conversations: Q&A With Cureus Co-Founder Alex Muacevic

Dr. Alex Muacevic Cureus Co-founder and Co-editor-in-chief

Alexander Muacevic is the Medical Director of the European Cyberknife Center in Munich, Germany and holds an academic teaching position at the University of Munich Hospitals. Dr. Muacevic is a board-certified neurosurgeon and radiosurgeon and his main clinical and scientific interest is full body radiosurgery using advanced image-guided robotic technology. In addition to earning a European Neurosurgery Certificate, Dr. Muacevic has published over 100 scientific contributions including peer-reviewed articles, book chapters and congress proceedings. Dr. Muacevic is also a member of several academic societies and president of the International Radiosurgery Society containing over 700 members. Last, but not least, Dr. Muacevic is the Co-Founder and Co-Editor-in-Chief of the Cureus Journal of Medical Science.

Q: What was your first publishing experience like? 

A: I started with smaller retrospective studies around Gamma Knife radiosurgery and I remember it was tough as a junior resident to fulfill all of the scientific standards.  

Q: How did your relationship with Dr. John Adler begin?

A: We knew each other from neurosurgery meetings but got to work more closely together via the Radiosurgery Society and finally when we started our Cyberknife center in Munich in 2005.

Q: Has open science always been something you’ve been passionate about? 

A: No, this developed over time and was based on frustrations in the conventional publishing world with more and more bureaucratic hurdles.

Q: In your opinion, what are the greatest challenges facing Open Access publishing?

A: Getting wide spread acceptance in the academic world.

Q: Is there anything about Cureus that you are particularly proud of?

A: Of course! We started from scratch over 10 years ago with only four people working to publish one article a month and now we have a much larger team and are publishing close to 10,000 articles this year. A great team effort and achievement!

Q: Do you have any advice for first-time authors?

A: Take your time, try to be precise and correct, and learn from more experienced people. Perhaps a simple case report with Cureus is the ideal introduction to the academic world.  

Q: What are you looking for from Cureus peer reviewers?

A: A clear, concise and unbiased analysis of the paper in question.

Q: What is it like having Dr. Adler as a partner?

A: He is the best partner to have, as he is always open to strong arguments. I enjoy the fair battles we have behind the curtain to make Cureus a better journal each and every day.

Q: Why should researchers submit to Cureus?

A: Because it is the best and fastest way to get peer reviewed science out to the world. I might be biased but I don’t know any journal which is more comfortable and also fun to publish with.

Q: Are you currently working on any research? If so, what can you tell us about it?

A: We are working on multiple projects like SRS for Trigeminal Neuralgia, Meningiomas and Renal Cell Cancer.

Cureus Conversations: Q&A With Editor in Chief Dr. John Adler

Cureus Conversations: Q&A With Editor in Chief Dr. John Adler

Dr. John Adler is the Editor in Chief of the Cureus Journal of Medical Science and Dorothy and Thye King Chan Professor in Neurosurgery Emeritus at Stanford University.

In your opinion, what is wrong with the current system of medical publishing? 

So much of publishing is presently geared towards a small elite community of academic physicians who understand the rules of the process and have the most time to engage in the publishing “game”. This means that the ideas from these academics, many of whom are not necessarily accomplished clinicians in the real world, are most widely circulated. Of course much of this process is intended to support the academic tenure process, which needs to create at least the illusion that certain ideas are innovative as opposed to merely being the product of an observant physician. Part of this stems from an excessive reliance on statistics.

Why are some slow to embrace the Open Access philosophy?

For the above reasons, academic physicians who have dominated journals for generations are loath to see publishing democratized. Democratization threatens their exclusivity/power in communicating medical science to the world.

What motivated you to start the Cureus Journal of Medical Science?

Having spent a lifetime in academia I could see that many truly clever, experienced and innovative physicians living in the trenches of medicine had no voice within the broader world of healthcare.

“Ask Me Anything” with Dr. John Adler
Follow Cureus on YouTube for more videos.

How do you measure success at Cureus?

The number, quality and reach of the articles we publish, as well as how engaged readers are with the content within.

Why should doctors and researchers publish in Cureus?

Cureus’ makes it easier and cheaper to publish a peer reviewed article than was ever possible before.

What makes a strong approval editor? What do the Cureus editors look for when critiquing medical science?

Ultimately Cureus’ most important duty is to our readers. It is somewhat ironic that Cureus’ responsibility to readers transcends that of our physician “customers”, with whom our editorial team primarily interacts. With this understanding in mind, I like it when an approval editor understand this hierarchy of accountability, approaching an article first and foremost from the reader’s perspective. Their job is not to kill/reject articles but to make sure that by reading carefully they suss out any “BS”, so that the reader has less work to do. Having said that every article, every time, by every reader should be approached with some measure of skepticism. There are no absolute truths in science. This is why our mantra is to publish “credible” science allowing the best science to “pass the test of time”.

Are you currently working on any research?

As a matter of fact, I just co-authored the following article published in Cureus: Neuromodulation via Focal Radiation: Radiomodulation Update

Using Platelet-Rich Plasma (PRP)Therapy to Efficiently Reduce Beard Hair Loss

Platelet-Rich Plasma (PRP) therapy is one of the most recent scientific advancements in the field of hair restoration. It’s simple, painless and relies on activating your body’s own healing capacities. Here is what you need to know about this procedure:


What is Platelet-Rich Plasma (PRP) Therapy for beard hair loss?   


PRP therapy has already been successfully used for some time in treating other conditions, such as muscle, bone or joint injuries. However, it was only recently that its benefits in promoting hair growth and restoration have been scientifically verified. This quick and easy procedure involves drawing a little bit of your own blood, then using a special centrifuge to separate the substances in it. Once the nutrient-rich platelets, which are great at promoting tissue growth are isolated, they are injected into the balding areas on your chin. This leads to better vascularization, tissue healing and regeneration, which means your reinvigorated follicles will start producing a thick and healthy-looking beard.


The procedure is no more painful than the sting of any injection, it is not invasive and carries no more risks than your average jab. Because it is your own blood that you are using, there is no chance of the body rejecting the platelets.     


Who can benefit from PRP therapy for beard hair loss?


There is already mounting evidence that PRP can be very effective in treating androgenetic alopecia (male pattern baldness) in the beard area. However, new research indicates that it may also successfully treat alopecia areata of the beard – a relatively rare, auto-immune condition which leaves a pattern bald spots on your chin. 


PRP therapy can also help treat beard loss caused by trauma (if the scarring is not too severe), by resolved skin issues, or by aging. However, it is unlikely that this procedure will yield good results if your hair loss is caused by beard trichotillomania (pulling out your beard hair when stressed), chemotherapy, untreated dermatological conditions, extensive scarring etc. If you are unsure what is causing your beard hair to fall out or would like to be certain that PRP is the right choice for you, do not hesitate to schedule an appointment with a dermatologist.  


How much does PRP therapy for beard hair loss cost?

A good price-quality ratio, offered by the well-reputed Wimpole Clinic in London, starts at $449 per PRP session. Given that 3-4 sessions, spaced out 4 weeks apart are normally required, followed by a booster session after 6-12 months, you should probably consider setting aside around $2,000-3,000 for the procedure in the first
year.

Editor’s Note: This blog post was sponsored and contributed by Wimpole Clinic.

Since When is “Fast and Efficient” a Shortcoming?

This past winter, I was notified in a short email that a scientific journal directory intended to drop Cureus from its list of preferred Open Access journals. No matter how specious any claim to exclusivity might be, who doesn’t crave getting past the big burly doorman guarding “The Club”? I reached out to this burly “Editor-in-Chief” of a “fraternity of journals” asking him how and why he arrived at his decision. After six email requests over nearly five months, I finally received a terse three-sentence 72-word response. In the eyes of the “Editor-in-Chief”, Cureus’ primary shortcoming was “submission to publication times are extremely short and you advertise your speed.” Basically, as I interpret this email rejection, Cureus’ sin is that it’s just too damn fast and efficient. Ahh… yeah, I guess Cureus is guilty as charged.

Continue reading “Since When is “Fast and Efficient” a Shortcoming?”

Diet Tips for People Suffering from Psoriasis 

Editor’s Note: This blog post was contributed by Everyday Health.

Psoriasis is an autoimmune, chronic condition, characterized by skin changes and other systemic manifestations. Aside from the treatment, and avoidance of trigger factors, such as stress, your doctor might recommend a change in your diet. 

A healthy diet is something anyone should consider, not only those who suffer from psoriasis. However, if you have been diagnosed with this condition, diet changes might help you keep the associated symptoms under control. Keep on reading and discover a few diet tips that might be helpful.

Continue reading “Diet Tips for People Suffering from Psoriasis “

Our Founder & Editor-in-Chief won the AANS Cushing Award!

We are delighted to announce that Cureus Founder and Editor-in-Chief Dr. John Adler was presented with the American Association of Neurological Surgeons’ Cushing Award for Technical Excellence and Innovation in Neurosurgery!

DcNba_DUwAET-VU

Presented at the 2018 AANS annual meeting in New Orleans on Monday April 30th, the Cushing Award could well be considered the Nobel Prize for Neurosurgery. The award was established in 2013 to honor innovation, skill and technical prowess in the development of new procedures which have become part of the arsenal neurosurgeons use to treat disease or trauma. John’s formative role in founding Cureus, “a disruptive platform for creating and sharing medical knowledge” was cited during the award presentation. Here at Cureus we are proud to call John our leader as his lifetime of professional accomplishments, including the creation of Cureus, led him to this point.

Founded by Harvey Cushing, after which the award is named, the 2018 AANS Annual Scientific Meeting is attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals, the AANS Annual Scientific Meeting is the largest gathering of neurosurgeons in the nation, with an emphasis on the field’s latest research and technological advances.

Congratulations, John!

You Call it High Academic Standards, I Call it Racism

I’m not a big fan of identity politics, where, in my opinion, allegations of racism are too often used as a political cudgel to bludgeon an opponent. But sometimes it really is important to call out blatant racism, especially when there is a greater societal good at stake, such as in this case protecting the integrity of peer-reviewed science. I had this very “opportunity” thrown at me just last week.

To introduce our journal, and its unique crowd sourced quality score (SIQ) to new physician authors, Cureus utilizes email to reach specific communities of authors who have published articles in other Open Access journals, inviting them to promote the scoring of their articles via social media and email. While away on business in Beijing last week, I was surprised to see one email and two voicemails on my phone from a (unknown to me) senior and accomplished author in other journals. His messages quickly revealed a surprising anger over having his article promoted by Cureus. I replied with a brief email explaining how the Creative Commons copyright system supported such fair usage by Cureus, but this merely precipitated yet another profanity-laced email volley. Not wanting to inflame matters further, and even more so wanting to understand the true source of his angst, I decided to call the author. To say the call was unpleasant would be an understatement. I am a neurosurgeon and have fairly tough skin but it is never fun to have all kinds of profanity thrown at you, especially when you’re sure it is unjustified.

I let him vent a little, as my primary goal was figuring out why he was so upset. No matter how patiently I asked this guy to explain the source of his anger, he repeatedly deflected. Finally, after having asked multiple times, this rather accomplished researcher frustratingly blurted out that he did not want his article promoted “alongside the University of Pakistan.” In that instant, everything became clear. There is no institution named The University of Pakistan. Cureus, however, recently published several articles from South Asian-based institutions, namely India and Pakistan. What I suddenly realized is that this person was merely pissed (and seemingly offended) that his “aristocratic” article (allow me some artistic license here) might appear alongside “unworthy” South Asian articles. To put it more bluntly, this otherwise truly accomplished author was just a racist old fool.

In an effort to defuse the situation I complied with his request to remove his article. Upon further reflection I now feel a deep sense of gratitude to this old racist for providing me the opportunity to expose how racism—implicit and overt (like this case), sadly lurks in the background of all peer-reviewed journals. Truthfully I am amazed that so many in this day and age are still clueless about what is happening in medical science. As I sit writing this in a world-renowned Chinese hospital, I am surrounded by the very type of medical excellence that my racist critic deems unworthy of his association. A close American friend of mine (and Cureus editorial board member) is one of the premier pediatric cardiac surgeons in the world, having invented several important heart operations. He has visited several South Asian hospitals that have refined his original operation, enabling them to operate on vastly more patients than him, and do so at less than 10% the price of a U.S. hospital. In light of this, it strikes me as complete foolishness to restrict such important medical knowledge. Scholarly racism is utterly self-defeating for authors, readers and the world at large.

Although I could find no formal studies documenting the extent of racism within scholarly journals, there is a modest body of research and other evidence pointing towards the existence of sexism, as well as prejudice against non-academic physicians, in the world of academic publishing [1-3]. Perhaps it is time to formally study the extent of racial bias in peer-reviewed journals. Any takers?

Recently, the CEO of an authoritative digital health website shared an interesting statistic with me: 40% of the articles published in the New England Journal of Medicine, arguably the most important medical journal, originate within a 200 mile radius of the journal’s headquarters. No one would disagree that Boston, New York and New Haven are centers of academic excellence, but the medical community that dominates the NEJM represents but a tiny fraction of world physicians, thus excluding an immense amount of clinical experience and knowledge. Although such willful blindness or elitism is not as blatant as the prejudice exhibited by my new acquaintance, does a hugely influential and even entitled societal institution like the NEJM not have a responsibility to open itself up to more of the world of medicine?

While I will continue to respect the world’s leading medical journals for the important work they publish, I remain proud that Cureus serves the vast numbers of physicians truly in the trenches of medicine who have been disenfranchised through what might be best termed “scholarly elitism.” Lastly, I want to thank this narrow-minded dolt for reminding me yet again why Cureus’ mission is so important to the world of medicine.

References:

1). Pololi LH, Civian JT, Brennan RT, Dottolo AL, Krupat E. “Experiencing the Culture of Academic Medicine: Gender Matters, A National Study.” J Gen Intern Med. 2012 Aug 31; [Epub ahead of print] PMID: 22936291. [PMC free article] [PubMed]

2) http://www.sciencemag.org/news/2015/05/plos-one-ousts-reviewer-editor-after-sexist-peer-review-storm

3) From abstract to impact in cardiovascular research: Factors predicting publication and citation. Eur Heart J. 2012 Winnik S, Raptis DA, Walker JH, Hasun M, Speer T, Clavien PA, et al. From abstract to impact in cardiovascular research: Factors predicting publication and citation. Eur Heart J. 5 June 2012 [Epub ahead of print] PMID: 22669850. [PMC free article] [PubMed]

Cureus Peer Review Just Got a Heck of a Lot Easier

We’re pleased to announce the launch of our brand new, built-from-the-ground-up peer review tool! Any article submission started today will utilize the new system while in peer review.

Previously, we had used a third-party software tool called Crocodoc for article peer review. Our team has been hard at work creating our own proprietary system that makes reviewing an easier, more intuitive experience.

Similar to Google Docs or Microsoft Word, this new system enables reviewers to highlight text and leave comments. Each reviewer’s comments will be displayed via a unique highlighted color, while also allowing for overlapping comments.

Adding a comment
Adding a comment

Only articles created and submitted after the release will utilize this new system. All articles created before the release will still use our original peer review system. As such, please don’t be alarmed if your review experience changes from article to article!

Viewing a comment
Viewing a comment

Between the peer review and submission systems, we have now overhauled the entire publishing process in the past five months. We’re confident that submitting and reviewing articles with Cureus is easier than it has ever been, but we won’t stop working to make your experience better. Stay tuned for more exciting updates as we continue to tweak and enhance the Cureus Journal of Medical Science. Thanks for your support!

– The Cureus Team

Questions about the new peer review system? Drop us a note at support@cureus.com and we’ll get back to you ASAP.